Literature DB >> 8044791

Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.

G Monti1, M C Jaurand, I Monnet, P Chretien, L Saint-Etienne, L Zeng, A Portier, P Devillier, P Galanaud, J Bignon.   

Abstract

In vivo production of monokines was analyzed in 17 human malignant pleural mesotheliomas. High concentrations of interleukin 6 (IL-6) were detected in pleural effusions, contrasting with low levels of IL-1 beta and tumor necrosis factor alpha. This production arose from malignant cells, as shown by immunochemical analysis of pleural cells and by production of IL-6 by mesothelial cell lines. Intrapleural administration of recombinant human gamma-interferon to six patients led to a marked decrease in intrapleural IL-6 concentrations in all cases. This treatment was associated with in situ activation of macrophages and cytotoxic T-lymphocytes, as indicated by increased intrapleural neopterin and soluble CD8 concentrations. In vitro gamma-interferon had no effect on the production of IL-6 by mesothelial cell lines but decreased the growth of 3 of 6 mesothelioma cell lines. These results indicate that systemic manifestations of malignant mesothelioma, including fever, cachexia, and thrombocytosis may be related to the production of IL-6 by malignant cells, and that local gamma-interferon infusion may reduce this production by stimulating antitumoral immunity and/or by directly decreasing the proliferation of malignant cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  CREB-induced inflammation is important for malignant mesothelioma growth.

Authors:  Catherine M Westbom; Anurag Shukla; Maximilian B MacPherson; Elizabeth C Yasewicz; Jill M Miller; Stacie L Beuschel; Chad Steele; Harvey I Pass; Pamela M Vacek; Arti Shukla
Journal:  Am J Pathol       Date:  2014-08-08       Impact factor: 4.307

Review 2.  The role of interleukin-6 in malignant mesothelioma.

Authors:  Siti N Abdul Rahim; Gwo Y Ho; Jermaine I G Coward
Journal:  Transl Lung Cancer Res       Date:  2015-02

3.  Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.

Authors:  Jedd M Hillegass; Arti Shukla; Sherrill A Lathrop; Maximilian B MacPherson; Stacie L Beuschel; Kelly J Butnor; Joseph R Testa; Harvey I Pass; Michele Carbone; Chad Steele; Brooke T Mossman
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

Review 4.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.

Authors:  Arti Shukla; Jill M Miller; Christopher Cason; Mutlay Sayan; Maximilian B MacPherson; Stacie L Beuschel; Jedd Hillegass; Pamela M Vacek; Harvey I Pass; Brooke T Mossman
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

6.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

Authors:  T Nakano; A P Chahinian; M Shinjo; A Tonomura; M Miyake; N Togawa; K Ninomiya; K Higashino
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.

Authors:  Y Soini; K Kahlos; A Puhakka; E Lakari; M Säily; P Pääkkö; V Kinnula
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

Review 8.  Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.

Authors:  Melanie Vogl; Anna Rosenmayr; Tomas Bohanes; Axel Scheed; Milos Brndiar; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.